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1. Introduction 
Cancer has become one of the most common causes of death in industrialized countries and 
has been defined as the medical challenge of our times. In 2008, 12.7 million new cancer 
cases and 7.6 million deaths from cancer worldwide have been reported (Ferlay et al., 2010). 
These authors also estimate that by 2020, approximately 17 million new cancer cases will be 
diagnosed, and 10 million cancer patients will die. Evidences have shown that as many as 
35% of these cases may be related to dietary factors (Manson, 2003), and thus, cancer can be 
prevented by modifications of nutritional and lifestyle habits. The rising prevalence of 
cancer worldwide and the corresponding rise in health care costs is propelling interest 
among researchers and consumers for multiple health benefits of food compounds, 
including reduction in cancer risk and modification of tumour behaviour (Béliveau, 2007; 
Kaefer and Milner, 2008). Epidemiological evidence, cell culture and animal tumour model 
studies have demonstrated that a large number of natural compounds present in the diet 
could lower cancer risk and even sensitize tumour cells in anti-cancer therapies (de Kok et 
al., 2008). Daily intake of food rich in anticancer molecules could be compared to a 
preventive, non-toxic version of chemotherapy that is harmless to the physiology of normal 
tissue and stops microtumours (Béliveau, 2007).  
Phytochemicals are compounds present in plant foods with capacity to affect and regulate 
multiple key proteins involved in regulation of cellular proliferation, differentiation, 
apoptosis, angiogenesis or metastasis, and thus, to affect the different carcinogenesis stages 
(Fimongnari et al., 2008; Ramos, 2008; van Breda et al., 2008). Chemopreventive and 
chemotherapeutic properties against human cancers have been revealed for different 
phytochemicals, such as epigallocatechin gallate [(-)-EGCG] (green tea polyphenol), 
genistein (soybean), apigenin (celery, parsley), isothiocyanates (broccoli), anthocyanins 
(berries), quercetin (onions), kaempferol (broccoli, grapefruits), curcumin (turmeric), diallyl 
trisulfide (garlic), and lycopene (tomatoes) (Chen and Dou, 2008; Yang et al., 2008; 
Fimognari et al., 2008; Singh and Goyal, 2008; Ramos, 2008; Seki et al., 2008). These 
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molecules have become an invaluable treasure in cancer prevention and chemotherapy, and 
further research is currently under way to explore their properties and mechanisms of 
action. 
2. Soybean and cancer 
Soybean (Glycine max) is an ancient legume consumed worldwide, but most commonly in 
Asian countries, such as China, Japan, Korea, Taiwan and Indonesia. Populations from these 
countries consume an average of 20 to 80 g of traditional soy foods daily in many forms, 
including soybean, soybean sprouts, toasted soy protein flours, soy milk, tofu, and 
fermented soy products, such as tempeh, miso, natto, soybean paste and soy sauce (Coward 
et al., 1993; Wang and Murphy, 1994). This intake equates to a daily intake of between 25 
and 100 mg total isoflavones (Messina et al., 2006) and between 8 and 50 g soy protein 
(Erdman Jr. et al., 2004). Western populations consume much less soy, only about 1 to 3 g 
daily, and this is mostly in processed forms, such as soy drinks, breakfast cereals, energy 
bars and soy "burgers" (Fournier et al., 1998).  
Epidemiological evidences have demonstrated an association between the consumption of 
soybean and improved health, particularly as a reduced risk for cardiovascular diseases 
(Anderson et al., 1999) and cancer, such as breast, prostate, endometrial, lung, and bladder 
cancer (Swanson et al., 1992; Wu et al., 1996; Goodman et al., 1997; Jacobsen et al., 1998; 
Zheng et al., 1999; Kolonel et al., 2000; Sun et al., 2002). Moreover, a number of animal 
models support anticancer properties of soy which constituents have been shown to 
suppress tumour growth in a variety of tissues including skin, bladder, mammary and 
prostate (Messina and Flickinger, 2002). In last decades, studies have isolated and identified 
an array of biologically active compounds or phytochemicals contained in soybean with 
cancer preventive effects. Genistein, daidzein and glycitein are the three major isoflavonoids 
found in soybean and soy products which properties have been extensively studied (Park 
and Surh, 2004). Large bodies of epidemiological studies have shown people consuming 
high amounts of these soy isoflavonoids in their diets have lower rates of several cancers, 
including breast, prostate and endometrial cancer (Lof and Weiderpass, 2006). In animal 
models, these compounds have been reported to inhibit the development of different types 
of tumors (Barnes et al., 1990; Li et al., 1999), but the results are not completely conclusive. 
Isoflavones exert both hormonal and non-hormonal action in the prevention of cancer, but 
the mechanism by which these compounds exert these chemopreventive properties is not 
yet clear and is currently a hot topic for research. The hormonal action of isoflavones has 
been postulated to be through a number of pathways, which include the ability to inhibit 
many tyrosine kinases involved in regulation of cell growth, to augment transformation 
growth factor- which inhibits the cell cycle progression, as well as to influence the 
transcription factors that are involved in the expression of stress response-related genes 
involved in programmed cell death (Akiyama et al., 1987; Zhou and Lee, 1998). Other non-
hormonal mechanisms by which isoflavones are believed to exert their anticarcinogenic 
effects are via their anti-oxidant, anti-proliferative, anti-angiogenic and anti-inflammatory 
properties (Gilani and Anderson, 2002).  
During last years, soybean proteins and peptides have attracted attention as drug 
candidates owing to their possession of certain key advantages over alternative 
chemotherapy molecules. Soy protein itself, which is lower in sulfur amino acid content 
than animal protein, has been shown to inhibit the development of carcinogen-induced 
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tumors in animals (Koski, 2006). Soybean proteins also can be a source of bioactive peptides 
with diverse and unique health benefits that can be used in the prevention of age-related 
chronic disorders, such as cardiovascular disease, obesity, decrease immune function and 
cancer. In contrast to most small-molecule drugs, peptides have high affinity, strong 
specificity for targets, low toxicity and good penetration of tissues (Bhutia and Maiti, 2008). 
Soy proteins and peptides have become one group of nutraceuticals that shows potential 
results in preventing the different stages of cancer including initiation, promotion, and 
progression (Table 1) (de Mejia and Dia, 2010a). Bowman–Birk protease inhibitor (BBI) is a 
polypeptide with 71 amino acids which chemopreventive properties have been 
demonstrated in both in vitro and in vivo bioassay systems (Losso, 2008). As a result of this 
evidence, BBI acquired the status of "investigational new drug" from the FDA in 1992, and 
large-scale human trials are currently undergoing to evaluate its use as an anticarcinogenic 
agent in the form of BBI concentrate (BBIC) (Armstrong et al., 2000, 2003; Meyskens, 2001). 
These studies have shown that BBIC is well-tolerated by the patients and led to promising 
results for prostate and oral carcinomas. BBIC is also being used to investigate its efficacy in 
the treatment of benign prostatic hyperplasia and ulcerative colitis (Kennedy, 2006). Kunitz 
trypsin inhibitor (KTI) is another protease inhibitor originally isolated from soybean. The 
biological significance of KTI in carcinogenesis is mainly attributed to its ability to suppress 
invasion and metastasis of cancer cells (de Mejia and Dia, 2010a). Recently, there has been 
increased interest in the potential health benefits of other bioactive polypeptides and 
proteins from soybean, including lectins and lunasin. Soy lectins are a significant group of 
biologically active glycoproteins that have been shown to possess cancer chemopreventive 
activity in vitro, in vivo and in human case studies (de Mejia et al., 2003). The suggested 
mechanisms of action for lectins include their effect on tumoral cell membranes, the 
reduction in cell proliferation, the induction of tumor-specific cytotoxicity of macrophages 
and the induction of apoptosis. Another suggestion is that lectins could have a strong effect 
on the immune system by altering the production of various interleukins (de Mejia and 
Prisecaru, 2005). There is still much to learn about the effects of soybean lectins on cancer 
risk. However, they are currently being used as therapeutics agents in cancer treatment 
studies and this area of research holds considerable potential. Lunasin is a novel peptide, 
identified in soybean, which chemopreventive activity has been recently reported. The 
purpose of this work is to summarize the possible benefits of lunasin as a chemopreventive 
agent as well as its demonstrated mechanisms of action. 
 
Soybean 
component 
Cell line/Mouse 
model/Human model 
Chemopreventive activity Reference 
Bowman-Birk 
protease 
inhibitor 
Human osteosarcoma 
U2OS cells 
 cell proliferation, arrest cell 
cycle, apoptosis induction,  
expression of C×43 mRNA 
Saito et al., 
(2007) 
Human ovarian 
sarcoma M5067 cells in 
mice 
 cell proliferation,  expression 
of C×43 mRNA 
Sakurai et al., 
(2008) 
Human breast cancer 
MCF-7 cells 
Arrest cell cycle,  proteasome 
chymotrypsin-like activity,  
expression of p27 and p21, 
inactivation of ERK1/2 
Chen et al., 
(2005) 
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Soybean 
component 
Cell line/Mouse 
model/Human model 
Chemopreventive activity Reference 
phosphorylation 
 cell proliferation 
Ho and Ng, 
(2008) 
DMBA-induced 
carcinogenesis in 
cultured mouse 
mammary gland 
Inhibition of breast carcinogenesis Du et al., (2001) 
Human prostate cancer 
cells 
 cell proliferation, invasion, and 
clonogenic survival 
Induction of apoptosis,  
expression of C×43, cleavage of 
caspase-3 
Kennedy et al., 
(2002) 
Tang et al., 
(2009) 
Prostate TRAMP mice 
model 
Inhibition of tumour  
development 
Tang et al., 
(2009) 
Dimethylhydrazine-
induced rat colon 
cancer 
Inhibition of colon  
carcinogenesis 
Kennedy et al., 
(2002) 
 
Induced rat prostate 
carcinogenesis 
Reduction of incidence of  
invasive and in situ  
prostate neoplasms 
McCormick et 
al., (2007) 
Hepatocellular 
carcinoma HepG2 cells
 cell proliferation Ho and Ng, 
(2008) 
Radiation-induced skin 
fibroblasts 
Blocking activation of tyrosine 
kinase and  epidermal growth 
factor 
Dittmann et al., 
(1998) 
NB4 promyelocytic 
leukemia cells 
 cell proliferation, arrest cell 
cycle, apoptosis induction, 
activation of the pathway of 
caspase-3 and -8 cascades 
Huang et al., 
(2004) 
Human colon HT-29 
cells 
 cell proliferation, inhibition of 
serine proteases 
Clemente et al., 
(2010) 
Oral leukoplakia in 
human trials 
Inhibition of oral carcinogenesis Armstrong et 
al., (2000, 2003); 
Meyskens et 
al., (2001) 
Kunitz trypsin 
inhibitor 
Ovarian cancer cells Suppression of cell invasion Kobayashi et 
al., (2004b) 
Ovarian HRA cells 
implanted in C57BL/6 
mice 
 total tumour burden in 
peritoneal metastasis 
Kobayashi et 
al., (2004b) 
Lewis lung  
carcinoma cells in 
C57BL/6 mice 
Inhibition of spontaneous 
metastasis 
Kobayashi et 
al., (2004a) 
Nasopharyngeal CNE-1 
and CNE-2 cells 
 cell growth, apoptosis  
induction 
Fang et al., 
(2010) 
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Soybean 
component 
Cell line/Mouse 
model/Human model 
Chemopreventive activity Reference 
Hepatocellular 
carcinoma HepG2 cells
 cell growth, apoptosis induction Fang et al., 
(2010) 
Lectins Different tumour cell 
lines 
 sensitivity to be attacked by 
macrophages 
Ganguly and 
Das (1994) 
Human colon cancer 
SW1222 and HT29 cells
 cell proliferation, blocked 
aggregation 
Jordinson et al., 
(1999) 
T-cell and B-cell 
leukemia 
Interaction with tumour cells Reysner (1983) 
Human gastric 
carcinomas 
Direct adhesion to cell 
membranes and receptors 
Terashima et 
al., (1997) 
Human melanoma 
A375 cells 
Induction of apoptosis by a 
caspase-dependent pathway 
Liu et al., 
(2009) 
Table 1. Effects of soybean Bowman-Birk protease inhibitor (BBI), Kunitz trypsin inhibitor 
(KTI) and lectins against cancer.  
2.1 Lunasin: discovery and beyond 
A novel peptide, which sequence is SKWQHQQDSCRKQKQGVNLTPCEKHIMEKIQG 
RGDDDDDDDDD, was originally isolated from soybean cotyledon (Galvez et al., 1997). 
Because of the properties initially discovered, this peptide was termed lunasin from the 
Tagalog word “lunas” for cure. Lunasin is composed of 43 amino acid residues with a 
unique sequence including the presence of a cell adhesion motif composed of RGD and a 
carboxylic acid tail composed of nine aspartic acid residues. Galvez and de Lumen (1999) 
reported the biological property of lunasin, formerly known as a soybean cDNA encoding 
small subunit peptide of 2S soy albumin. They showed that transfection of lunasin plasmid 
into different mammalian cells caused cell division arrest, abnormal elongation of spindle 
fiber, chromosomal fragmentation, and cell death or apoptosis. Moreover, treatment of 
synthetic lunasin showed preferential adherence of this peptide to chromatin, leading to 
disruption of kinetochore and inhibition of mitosis. This activity seems to be due to the 
binding of its negatively charged poly-D carboxyl end to the highly basic histones found 
within the nucleosomes of condensed chromosomes, probably to regions that contain more 
positively charged, such as the hypoacetylated chromatin found in telomeres and 
centromeres. Lunasin’s sequence also contains the motif RGD known to allow tumour cell 
attachment to the extracellular matrix (Ruoslahti and Pierschbacher, 1986). Peptides 
containing this motif have been reported to prevent metastasis of tumour cells by 
competitive adhesion to extracellular matrices (Akiyama et al., 1995). In the case of lunasin, 
this motif has been found to be essential for lunasin’s internalization into the nucleus of 
C3H10T1/2 cells, but it is completely unnecessary for internalization into the nucleus of 
NIH3T3 cells, suggesting that the role of RGD motif might be cell-line specific (Galvez et al., 
2001). These initial observations suggested a potential and promising chemopreventive role 
of lunasin in cancer prevention and led to successive studies designed and conducted to 
verify this hypothesis.  
Lunasin concentration in soybean depends mainly on cultivar and environmental factors 
including temperature and soil moisture. Analysis of five soybean cultivars grown at three 
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different temperatures and two soil moisture conditions showed that cultivar and 
temperature but not soil moisture significantly affected lunasin concentration in soy (Wang 
et al., 2008b). These authors reported that lunasin concentration of the five cultivars ranged 
from 7.5 to 10.4 mg/g flour, in which US cultivars Loda, Jack and Dwight showed higher 
values than French cultivars Queen and Imari. Cultivars grown at higher temperature of 28 
°C showed lowest lunasin concentration (8.1 mg/g flour) than those grown at intermediate 
temperature of 23 °C (9.2 mg/g flour) and low temperature condition (8.8 mg/g flour). A 
significant interaction was found between cultivar and temperature as well as soil moisture 
and cultivar in affecting lunasin concentration in soybean. Determination of lunasin 
concentration in 144 selected, diverse soybean accessions from the U.S. Department of 
Agriculture by enzyme linked immunosorbent assay showed that lunasin concentration 
ranged from 0.1 g to 1.3 g/100 g flour (de Mejia et al., 2004). Soybean seeds devoid of BBI 
also showed varying concentrations of lunasin ranging from 3.3 to 16.7 ng lunasin/mg seed 
indicating that lunasin is still produced on soybean seed even in the absence of BBI (de 
Mejia and Dia, 2010b). Analysis of lunasin in Korean soybean cultivar Taekwongkong 
showed that lunasin appears at 6 weeks after flowering (0.01 µg/g seed) with its highest 
level found at maturity with concentration of 0.12 µg/g seed (Park et al., 2005). Processing 
also affects lunasin concentration in soybean and soybean products. For instance, sprouting 
of soybean seed by soaking showed that lunasin starts decreasing 2 days after soaking and 
completely disappears after 7 days under both light and dark conditions (Park et al., 2005). 
de Mejia and co-workers (2004) showed that lunasin concentration of commercially 
available soy protein is in the range of 13 to 44 mg lunasin/g flour. Lunasin-enriched soy 
flour showed a concentration of 27.3 mg lunasin/g flour while isoflavone-enriched soybean 
products extracted with ethanol showed almost no lunasin which might be attributed to 
poor solubility of lunasin in ethanol. Another study conducted by Jeong et al. (2003) 
reported that defatted soybean flour had the lowest concentration of lunasin (5.5 mg 
lunasin/g protein) when compared with soy isolate (6.9 mg/lunasin/g protein) and soy 
concentrate (8.7 to 16.5 mg lunasin/g protein). They also showed that water-washed soy 
concentrate had higher lunasin concentration than alcohol-washed soy concentrate. These 
reports indicate that lunasin concentration in soybean products is affected by processing 
conditions. Recently, it has been found that environmental factors, such as germination time 
and temperature have a significant influence on the composition and concentration of 
bioactive compounds in germinated soybean flour from the Brazilian soybean cultivars BRS 
133 and BRS 258 (Paucar-Menacho et al., 2010b, c). These authors reported that protein 
concentration also affects the final distribution of nutrients and bioactive components in 
soybean, including lunasin (Paucar-Menacho et al., 2010a). 
The first study has demonstrated lunasin’s presence in US commercially available soy foods, 
including soy milk, infant formulas, tofu, bean curd, soybean cake, tempeh, and su-jae 
(Hernández-Ledesma et al., 2009a). As an example, Table 2 shows type, composition, origin 
and lunasin and BBI concentrations of different soy milk samples analyzed by these authors. 
Concentrations of two peptides in soy milk and other soybean products seem to be 
determined by the soybean variety and the process used during manufacturing, indicating 
that these two parameters can be used to control contents of these two peptides. Previously 
it had been demonstrated that large-scale processing of soy to produce different protein 
fractions influences lunasin concentration. This content varied from 12 to 44 mg lunasin/g 
of flour when different commercially available soy proteins were analyzed (de Mejia et al., 
2004; Jeong et al., 2003). 
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Sample 
No. 
Type  of  sample Composition-main 
ingredients 
Country Lunasin 
(mg/100 g 
product) 
BBI 
(mg/100 g 
product) 
Soy milk-
1 
Enriched soymilk Soybeans USA 15.7  1.3 33.1  4.2 
Soy milk-
2 
Organic original 
soymilk 
Soybeans, malted wheat 
and barley extract 
USA 18.9  2.6 27.1  3.4 
Soy milk-
3 
Organic fortified 
soymilk 
Soybeans, malted wheat 
and barley extract 
USA 14.2  1.1 24.7  4.3 
Soy milk-
4 
Organic plain 
soymilk 
Soybeans USA 13.8  2.6 45.7  7.2 
Soy milk-
5 
Organic 
unsweetened 
soymilk 
Soybeans USA 14.4  2.4 55.9  5.0 
Soy milk-
6 
Organic plain 
soymilk 
Soybeans USA 14.7  0.8 40.0  5.5 
Soy milk-
7 
Organic original 
soymilk 
Soybeans, rice syrup USA 13.7  0.9 30.3  3.7 
Soy milk-
8 
Organic plain 
soymilk 
Soybeans, soy protein 
isolate 
USA 13.9  1.0 25.9  4.2 
Soy milk-
9 
Organic original 
soymilk 
Soybeans, malt syrup USA 18.3  2.4 23.1  3.0 
Soy milk-
10 
Organic original 
soy drink 
Soybeans, barley extract USA 10.7  0.8 7.2  1.5 
Soy milk-
11 
Fortified  
soymilk 
Soybeans USA 12.3  0.8 18.8  2.7 
Soy milk-
12 
Unsweetened 
soymilk 
Soybeans Singapore 11.8  1.3 n.d. 
Soy 
formula-1 
Soy-based 
formula 
Corn syrup, soy protein 
isolate 
USA 4.1  0.4 n.d. 
Soy 
formula-2 
Organic soy 
formula 
Corn syrup, soy protein USA 2.8  0.2 n.d. 
Soy 
formula-3 
Organic soy 
formula 
Rice syrup, soy protein 
concentrate 
USA 1.5  0.1 n.d. 
Tofu-1 Soft Tofu Soybeans USA 9.62  0.87 4.63  1.76 
Tofu-2 Soft Tofu Soybeans USA 7.34  1.04 3.72  0.21 
Tofu-3 Silken Tofu 
Kinugoshi 
Soybeans USA 9.60  0.74 12.41  2.11 
Tofu-4 Silken Tofu Soybeans USA 4.41  0.49 11.87  1.53 
Tofu-5 Silken Tofu Soybeans USA 3.69  0.49 5.92  1.15 
Tofu-6 Medium firm 
Tofu 
Soybeans USA 14.30  1.80 4.91  0.53 
Tofu-7 Organic  
Medium firm 
Tofu 
Soybeans USA 6.66  1.29 4.19  0.54 
Tofu-8 Firm Tofu Soybeans USA 3.50  0.23 8.23  0.58 
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Sample 
No. 
Type  of  sample Composition-main 
ingredients 
Country Lunasin 
(mg/100 g 
product) 
BBI 
(mg/100 g 
product) 
Tofu-9 Extra firm tofu 
Chinese style 
Soybeans USA 3.66  0.12 4.57  0.55 
Tofu-10 Baked tofu Soybeans, soy sauce 
(wheat) 
USA 5.47  0.34 2.94  0.48 
Tofu-11 Fried tofu Soybean, soybean oil, soy 
sauce 
USA 0.37  0.05 n.d. 
Tofu-12 Dry tofu Soybeans Taiwan 2.50  0.27 n.d. 
Natto-1 Natto Fermented soybeans 
(Bacillus subtilis natto) 
Japan n.d. n.d. 
Miso-1 Organic Miso Soybeans, rice, 
Aspergillus oryzae 
Japan n.d. n.d. 
Tempeh-1 Organic soy 
tempeh 
Soybeans, Rhizopus 
oligosporus 
USA n.d. n.d. 
Tempeh-2 Organic soy 
tempeh 
Soybeans, brown rice, R. 
oligosporus 
USA 8.19  0.42 n.d. 
Tempeh-3 Organic soy 
tempeh-flax 
Soybeans, flaxseed, 
brown rice, R. oligosporus
USA 6.12  0.40 n.d. 
Tempeh-4 Organic soy 
tempeh-rice 
Soybeans, brown rice, R. 
oligosporus 
USA n.d. n.d. 
Bean 
curd-1 
Marinated bean 
curd 
Soybeans, soy sauce Taiwan 9.53  1.01 14.65  0.60 
Bean 
curd-2 
Soybean curd 
noodle 
Soybeans Taiwan n.d. n.d. 
Soybean 
cake-1 
Deep fried 
soybean cake 
Soybeans, soybean oil USA 1.91  0.25 6.57  0.41 
Soybean 
cake-2 
Baked soybean 
cake 
Soybeans, soy sauce, 
sesame oil 
USA 1.14  0.15 0.73  0.05 
Table 2. Type, composition, country of origin and lunasin and BBI concentrations 
ofcommercial soy food products 
2.1.1 Lunasin’s bioavailability 
An important property of an ideal cancer preventive agent is its ability, after being orally 
administrated, to escape gastrointestinal digestion and to be absorbed through the 
bloodstream reaching the target tissues and organs in an intact and active form. To date, 
different lunasin’s bioavailability studies conducted in both animals and humans have 
shown promising results. First studies carried out in mice and rats fed lunasin-enriched soy 
protein found that 35% of ingested lunasin reaches the target tissues and organs in an intact 
and active form (Jeong et al., 2007a). It has also been reported that BBI and KTI contained in 
soybean protect lunasin against gastrointestinal digestion, making this peptide bioavailable 
to exert its chemopreventive properties (Park et al., 2007). Hsieh and co-workers reported 
that synthetic 3H-labeled lunasin was bioavailable after its oral administration to CD-1 mice, 
reaching different tissues, including lung, mammary gland, prostate, and brain (Hsieh et al., 
2010a). These authors also found that lunasin extracted from the blood and liver of lunasin-
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enriched soy flour-fed rats was bioactive and able to suppress foci formation in the same 
concentration as synthetic lunasin. Lunasin from other seeds have also shown stability 
towards pepsin and pancreatin in vitro digestion (Jeong et al., 2009; Jeong et al., 2010a). 
These authors demonstrated lunasin’s presence in different organs, such as liver, kidney, 
and blood of rats fed with lunasin-enriched rye. First bioavailability study conducted in 
humans has demonstrated that 4.5% of lunasin ingested in the form of soy protein reaches 
plasma of healthy volunteer men (Dia et al., 2009a). Results from this study are relevant in 
supporting future clinical trials to demonstrate lunasin’s cancer preventive properties. 
2.1.2 Lunasin against cancer: in vitro and in vivo evidence 
Cell culture experiments have demonstrated that lunasin prevent mammalian cells 
transformation induced by chemical carcinogens without affecting morphology and 
proliferation of normal cells. Galvez and co-workers (2001) found that lunasin suppresses 
foci formation in 7,12-dimethylbenz[a]anthracene (DMBA) and 3-methylcholanthrene 
(MCA)-induced C3H10T1/2 cells. Similar results have been found by Hsieh and co-workers 
(2011) in DMBA-induced NIH3T3 cells. This suppressive effect is significantly higher than 
that exerted by the well-known cancer preventive BBI on an equimolar basis. Lunasin's 
inhibitory effects have been also found in C3H10T1/2 and NIH3T3 cells transformed by 
oncogenes and genes that inactivate tumor suppressor proteins (Galvez et al., 2001; Jeong et 
al., 2003; Lam et al., 2003). Ras-oncogenes are frequently activated in human cancers, 
playing a central role in the ras/mitogen activated protein kinase (MAPK) signalling 
cascade, which has a pivotal role in cell proliferation, differentiation, survival and cell death 
(Barbacid, 1987; Malumbres and Barbacid, 2003). Lunasin has been shown to prevent 
transformation of NIH3T3 cells transfected with an inducible form of ras-oncogene (Jeong et 
al., 2003). Moreover, addition of lunasin to mouse fibroblasts NIH3T3 stably transfected 
with the viral oncogene E1A has been reported to suppress foci formation and to increase 
protein p21 level (Lam et al., 2003). Oncogene E1A has been associated with human tumours 
because of its ability to inactivate the tumour suppressor retinoblastoma protein (RB) 
causing cell cycle arrest and cells transformation (Helt and Galloway, 2003).  
These first results made lunasin to be considered as a “watchdog” agent that sits in the 
nucleus of the cells and effectively does nothing when there is no transformation event. 
When a transformation event occurs, lunasin is triggered into action (de Lumen, 2005). 
However, recent studies carried out in our laboratories have revealed that lunasin also acts 
on established cancer cell lines. Lunasin purified from defatted soybean flour by 
combination of ion-exchange chromatography and size exclusion chromatography (Dia et 
al., 2009b) showed potent activity against different human colon cancer cells. Lunasin 
caused cytotoxicity in four different human colon cancer cell lines with IC50 values of 13.0 
µM for KM12L4 cells, 21.6 µM for RKO cells, 26.3 µM for HCT-116 cells and 61.7 µM for HT-
29 cells (Dia and de Mejia, 2011). These values showed that lunasin is most potent in killing 
the highly metastatic KM12L4 colon cancer cells than any other colon cell lines used in this 
study. Crystal violet staining of HT-29 colon cancer cells showed that starting at 10 µM, 
lunasin caused changes in the morphology and number of viable cancer cells (Dia and de 
Mejia, 2010). Also, treatment of the oxaliplatin-resistant variants (OxR) of these colon cancer 
cells showed IC50 values of 34.7 µM for KM12L4OxR, 38.9 µM for RKOOxR and 31.6 µM for 
HCT-116OxR while HT-29OxR was not affected by lunasin treatment. It has been also 
demonstrated that lunasin causes a dose-dependent inhibition of the growth of estrogen-
independent breast cancer MDA-MB-231 cells, with an IC50 value of 181 M (Hsieh et al., 
www.intechopen.com
 Soybean and Health 
 
154 
2010b). Studies carried out to establish a structure/activity relationship showed an IC50 
value of 138 M for the 21 amino acid sequence localized at the C-terminus of lunasin, thus 
being the main responsible for lunasin’s inhibitory effect on breast cancer cells proliferation 
(Hernández-Ledesma et al., 2011). Lunasin’s suppressive effect on cell growth has been also 
found in L1210 leukemia cells, with an IC50 value of 14 M (Wang et al., 2008a). 
Chemopreventive properties of lunasin have been also demonstrated in vivo. First animal 
model used to demonstrate these properties was a chemical carcinogen induced SENCAR 
skin cancer mouse model (Galvez et al., 2001). These authors demonstrated that 250 g 
lunasin/week, topically administered to SENCAR mice treated with DMBA and 
tetradecanoylphorbol-13-acetate (TPA), suppresses skin tumor incidence, decreases tumor 
yield/mouse and increases the tumor latency period by 70% compared with the untreated 
control. Moreover, lunasin was found to delay the appearance of papilloma by slowing 
down epidermal cell proliferation in mouse skin in the presence of DMBA (Hsieh et al., 
2004). Promising results have been also found when lunasin acts in vivo against breast 
cancer. Our first findings show a relevant inhibitory effect on mammary tumours 
development when a lunasin-enriched diet is administered to DMBA-induced mice (Hsieh 
et al., 2010c). Moreover, lunasin reduces tumour incidence and generation, as well as 
tumour weight in a xenograft mouse model using human breast cancer cells. Tumour 
incidence was reduced by 49% and 33%, in nude mice transplanted with MDA-MB-231 cells 
and administered i.p. injections of lunasin, at 20 mg/kg and 4 mg/kg body weight, 
respectively, compared with the vehicle-treated group, while no effects were observed when 
mice were treated with BBI (Hsieh et al., 2010a). In the breast tumour histological sections, 
lunasin was found to inhibit cell proliferation and to induce cell apoptosis. These studies 
make lunasin a promising alternative to prevent and/or treat skin and breast cancer. 
Further research should be needed to demonstrate chemopreventive role of this peptide 
against other types of cancer, as well as to elucidate its in vivo mechanism of action. 
2.1.3 Mechanism of lunasin’s action 
Initially, lunasin was found to act through an epigenetic mechanism of action. This peptide 
has been demonstrated to compete with different histone acetyltransferase enzymes (HATs), 
such as yGCN5 and PCAF, inhibiting the histones acetylation and repressing the cell cycle 
progression (Jeong et al., 2002, 2007b, c). Acetylation has been linked to chromatin 
disruption and the transcriptional activation of genes, being thus considered one of the most 
important epigenetic modifications acting on signal transduction pathways including those 
involved in cancer development (Dwarakanath et al., 2008; Dalvai & Bystricky, 2010). 
Mistargeted and deregulated HATs activities, as well as their over-expression have been 
reported to play an important role in several human cancers (Gayther et al., 2000). Lunasin 
has been reported to inhibit histone acetylation in mammalian cells induced by chemical 
carcinogens and/or viral oncogenes that provoke inactivation of tumor suppressor proteins, 
such as RB, p52 and pp32. When lunasin is present in the cell nucleus, it acts as a surrogate 
tumor suppressor and tightly binding to deacetylated core histones and disrupting the 
balance between acetylation-deacetylation, which is perceived by the cell as abnormal and 
leads to cell death (de Lumen, 2005). Recently, studies carried out with human breast cancer 
MDA-MB-231 cells have demonstrated that lunasin inhibits histones H3 and H4 acetylation 
in these cells (Hernández-Ledesma et al., 2011), being more potent than other compounds 
which HATs inhibitory activity has been associated with their chemopreventive role 
(Balasubramanyam et al., 2003, 2004a, b). Structure/activity relationship have demonstrated, 
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in one hand, that the percentage of inhibition caused by lunasin is specific of lysine position 
sensitive to be acetylated, and in another hand, that lunasin’s sequence is essential for 
inhibiting H4 acetylation whereas poly-D sequence is the main active sequence responsible 
for H3 acetylation inhibition (Hernández-Ledesma et al., 2011). Figure 1 shows the activity 
of each lunasin-related fragment on histone binding and/or acetylation at different Lys 
positions. 
Studies conducted with different tumour cell lines have demonstrated new mechanisms for 
lunasin’s chemopreventive action. Studies with colon cancer HT-29 and KM12L4 cells have 
shown that lunasin caused a G2/M phase arrest in the cell cycle and induction of the 
mitochondrial pathway of apoptosis (Dia and de Mejia, 2010). The G2/M phase cell cycle 
arrest was attributed with concomitant increase in the expression of the p21 protein in HT-
29 colon cancer cells while both p21 and p27 protein expressions were up-regulated by 
lunasin treatment in KM12L4 colon cancer cells. Measurement of protein expressions 
associated with mitochondrial pathway of apoptosis showed that lunasin treatment affected 
the ratio of Bax to Bcl-2 by up-regulating the pro-apoptotic Bax and down-regulating the 
expression of the anti-apoptotic Bcl-2. This might be attributed to increase in the expression 
of the pro-apoptotic form of clusterin known as nuclear clusterin which is positively affected 
by increase in p21 expression. Translocation of Bax into the mitochondrial membrane 
resulted in the release of cytochrome c as shown by increase in the expression of cytosolic 
cytochrome c in KM12L4 colon cancer cells treated with lunasin. This resulted in an increase 
in the activity of caspase-9 and the activity of the executioner of apoptosis caspase-3 in both 
HT-29 and KM12L4 colon cancer cells treated with lunasin when compared to untreated 
cells. We proposed the mechanism by which lunasin can induce apoptosis in human colon 
cancer cells as shown in Figure 2. 
 
 
Fig. 1. Amino acids sequence of lunasin peptide and demonstrated histones H3 and H4 
acetylation inhibitory activity of the different fragments of its sequence 
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Fig. 2. Proposed mechanism by which lunasin induces apoptosis in human colon cancer 
cells. 
The RGD motif present in the lunasin structure is a recognition site for integrin receptors 
present in the extracellular matrix (ECM). Integrins are heterodimeric receptors associated 
with cell adhesion, ECM and cancer metastasis. Treatment of KM12L4 colon cancer cells 
with lunasin resulted in the modification on the expression of 62 genes associated with ECM 
and cell adhesion, of which 48 genes were up-regulated and 14 genes were down-regulated 
(Dia and de Mejia, 2011a). Lunasin down-regulated the gene expression of collagen type VII 
┙1, integrin ┚2, matrix metalloproteinase 10, selectin E and integrin ┙5 by 10.1-, 8.2-, 7.7-, 
6.5- and 5.0-fold, respectively compared to the untreated KM12L4 colon cancer cells. On the 
other hand, the expression of collagen type XIV ┙1 was up-regulated upon lunasin 
treatment by 11.6-fold (Dia and de Mejia, 2011). These results suggest a potential role of 
peptide lunasin in cancer metastasis.  
Lunasin has been also demonstrated to arrest cell cycle and to induce apoptosis in  breast 
cancer MDA-MB-231 cells (Hsieh et al., 2010b). These authors demonstrated that lunasin 
modulates expression of different genes and proteins involved in cell cycle, apoptosis and 
signalling transduction. Inhibition of deregulated cell cycle progress in cancer cells is being 
considered an effective strategy to delay or halt tumour growth. It is well established that 
cyclins play a positive role in promoting cell cycle transitions via their ability to associate 
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with their cognate cyclin-dependent kinases (CDKs) and to activate them (Kato et al., 1993). 
Over-expression of cyclins D1 and D3 is one of the most frequent alterations present in 
breast tumours (Sutherland and Musgrove, 2004). Cyclins D interacts with CDK4 or CDK6 
to form a catalytically active complex, which phosphorylates RB to free active E2F (Qu et al., 
2003). Up-regulation of RB gene expression (Hsieh et al., 2010b), as well as inhibition of RB 
phosphorylation (Jeong et al., 2007b) have been linked to lunasin’s arresting effect on breast 
cancer cells cycle progress. Down-regulation of cyclins D1 and D3, and CDK4 and CDK6 
protein expression as well as modulation of expression of CDC25A, Caspase 8, and Ets2, 
Myc, Erbb2, PIK3R1 and Jun signaling genes in breast cancer cells might also contribute on 
this lunasin’s suppressive effect (Hernández-Ledesma et al., 2011; Hsieh et al., 2010b). 
Lunasin also showed cytotoxic effect in L1210 leukemia cells with an IC50 value of 14 µM. 
The mechanism involved was through arrest of cell cycle at G2/M phase with concomitant 
pro-apoptotic inducing property. The expressions of caspases-3, -8 and -9 were up-regulated 
by 12-, 6- and 6-fold respectively which resulted in the increase of percentage of L1210 
leukemia cells undergoing apoptosis from 2 to 40% (de Mejia et al., 2010). 
Lunasin has been found to exert anti-inflammatory and antioxidant activities that might 
contribute to its chemopreventive properties. First studies demonstrated that lunasin 
potently inhibits lipopolysaccharide (LPS)-induced production of pro-inflammatory 
mediators interleuquine (IL-6), tumor necrosis factor (TNF-), and prostaglandin E2 (PGE2) 
in RAW 264.7 cells through suppression of nuclear factor (NF)-B pathways (Hernández-
Ledesma et al., 2009b; de Mejia and Dia, 2009). It has been also reported that this peptide 
exert its anti-inflammatory activity through modulation of cyclooxygenase-2 (COX-2)/PGE2 
and inducible nitric oxide synthase (iNOS)/nitric oxide pathways (Dia et al., 2009b). 
Moreover, lunasin has been found to exert potent antioxidant properties, reducing LPS-
induced production of ROS by macrophage cells, and acting as a potent free radical 
scavenger (Hernández-Ledesma et al., 2009b). Recently, lunasin purified from Solanum 
nigrum L. has been found to protect DNA from oxidative damage by suppressing the 
generation of hydroxyl radical via blocking fenton reaction (Jeong et al., 2010). 
Silva-Sánchez and co-workers, (2008) reported for the first time the presence of a lunasin-
like peptide in amaranth protein fractions. Glutelin fraction in amaranth seeds had the 
highest lunasin concentration (3.0 g/g). Lunasin was also identified in albumin, prolamin 
and globulin amaranth protein fractions. 
Maldonado-Cervantes and co-workers, (2010) found that the amaranth lunasin-like peptide 
inhibited the transformation of NIH-3T3 cells to cancerous foci. The open reading frame of 
amaranth lunasin corresponds to a bifunctional inhibitor/lipid-transfer protein (LTP). There 
are many new intriguing questions about the function of lunasin in plants and its health-
promoting benefits that need further investigations. 
3. Conclusion 
Epidemiological evidence has demonstrated an association between the consumption of 
soybean and improved health, particularly reduced risk for cardiovascular diseases and 
cancer. In vitro as well as in vivo studies support the cancer preventive properties of soy and 
soy compounds responsible of these properties. This review has summarized the 
chemopreventive activity of proteins and peptides that contribute to reported cancer 
preventive effects of soybean. Among them, peptide lunasin holds a considerable potential. 
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This peptide, administered in soy proteins, has been demonstrated to be bioavailable after 
resisting gastrointestinal and serum degradation, and reaching blood and target organs in 
an intact and active form. Lunasin’s efficacy against leukemia, breast and colon cancer using 
cell culture models has been recently revealed. Animal experiments are being conducted to 
verify these in vitro properties, and to date, a promising role of lunasin against skin and 
breast cancer has been reported. Moreover, genomics, proteomics and biochemical tools are 
being applied to complete elucidate its molecular mechanism of action. Obtained results 
from all these studies make lunasin a good candidate for new generation of cancer 
preventive agents derived from foods. However, there is still much to be learned about 
lunasin’s effects on cancer prevention. The major challenge on the use of lunasin in treating 
cancer would be the conversion of in vitro and in vivo results into clinical outcomes. 
Therefore, it should be needed to design clinical trials that confirm lunasin’s 
chemopreventive properties against different types of cancer. Other aspects, such as 
searching for lunasin in other seeds, optimization of techniques to enrich products with this 
peptide and studying lunasin's interactions with other food constituents affecting its activity 
should also be conducted. 
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